NF1 is a debilitating genetic condition that affects one in every 3,000 to 4,000 individuals. It is caused by a spontaneous or inherited mutation in the NF1 gene and is associated with many symptoms, including soft lumps on and under the skin (cutaneous neurofibromas) and skin pigmentation (so-called ‘café au lait’ spots) and, in 30-50% of patients, tumours develop on the nerve sheaths (plexiform neurofibromas). 
This report contains market size and forecasts of Neurofibromatosis Type 1 in global, including the following market information:
Global Neurofibromatosis Type 1 Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Neurofibromatosis Type 1 Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Neurofibromatosis Type 1 companies in 2021 (%)
The global Neurofibromatosis Type 1 market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
10 mg Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Neurofibromatosis Type 1 include AstraZeneca and Merck etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Neurofibromatosis Type 1 manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Neurofibromatosis Type 1 Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neurofibromatosis Type 1 Market Segment Percentages, by Type, 2021 (%)
10 mg
25 mg
Global Neurofibromatosis Type 1 Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neurofibromatosis Type 1 Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Neurofibromatosis Type 1 Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Neurofibromatosis Type 1 Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Neurofibromatosis Type 1 revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Neurofibromatosis Type 1 revenues share in global market, 2021 (%)
Key companies Neurofibromatosis Type 1 sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Neurofibromatosis Type 1 sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
Merck